Matt Chapin

Ora, Inc

Matthew Chapin is Sr. VP, Corporate Development at Ora, Inc. In his role, Matt focuses on strategic initiatives, special projects, client programs involving co-development, structure and management of risk sharing, fund raising, and partnering/licensing. Matt has been in the ophthalmology industry for the past 20 years at Ora, holding positions across clinical studies and preclinical/toxicology development, product strategy, regulatory, project management, marketing support and business development. Matt has provided diligence and strategic support to investors and companies, and helped multiple virtual start-ups, biotech, and pharma companies transition from preclinical through pre-IND strategy/meetings and IND/Phase 2. Matt supported establishment of Ora Japan KK and was co-founder of a spin-off company Afferent that led to a $34m Series A financing of Aciex Therapeutics. Matt contributes a quarterly column in Review of Ophthalmology, Ophthalmic Product Development Insights. Ora provides a comprehensive range of turnkey development services to pharma, biotech, and start-ups, including; consulting, clinical, regulatory, preclinical, CMC, and integration of business development support, for developers, buyers, and investors.